[go: up one dir, main page]

MX2015011846A - Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades. - Google Patents

Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades.

Info

Publication number
MX2015011846A
MX2015011846A MX2015011846A MX2015011846A MX2015011846A MX 2015011846 A MX2015011846 A MX 2015011846A MX 2015011846 A MX2015011846 A MX 2015011846A MX 2015011846 A MX2015011846 A MX 2015011846A MX 2015011846 A MX2015011846 A MX 2015011846A
Authority
MX
Mexico
Prior art keywords
methods
mis protein
subject
another aspect
treatment
Prior art date
Application number
MX2015011846A
Other languages
English (en)
Inventor
K Donahoe Patricia
Vavvas Demetrios
Pepin David
Van Hoang Mien
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of MX2015011846A publication Critical patent/MX2015011846A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)

Abstract

La presente invención se relaciona a proteína MIS humana recombinante modificada que tiene segmentación mejorada y bioactividad incrementada y potencia incrementada como se compara con la proteína MIS humana de tipo silvestre. Otros aspectos de la invención se relacionan a métodos para prevenir y tratar cánceres, tales como cánceres que expresan el receptor de MIS tipo II (MISRII) al administrar a un sujeto una composición que comprende una proteína MIS humana recombinante. Otro aspecto de la presente invención se relaciona a métodos para disminuir los niveles de andrógeno en el plasma en un sujeto, y/o para el tratamiento de un sujeto con una enfermedad caracterizada por andrógeno en exceso. Otro aspecto proporciona composiciones farmacéuticas y kits y métodos para uso, que comprenden una proteína MIS humana recombinante. Otro aspecto de la presente invención se relaciona a métodos para disminuir la dosis de un agente quimioterapéutico al administrar el agente quimioterapéutico con la proteína MIS recombinante que disminuye la dosis efectiva del agente quimioterapéutico.
MX2015011846A 2013-03-12 2014-03-12 Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades. MX2015011846A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361777135P 2013-03-12 2013-03-12
PCT/US2014/024010 WO2014164981A1 (en) 2013-03-12 2014-03-12 Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
MX2015011846A true MX2015011846A (es) 2016-09-27

Family

ID=51659030

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011846A MX2015011846A (es) 2013-03-12 2014-03-12 Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades.

Country Status (14)

Country Link
US (2) US11084860B2 (es)
EP (1) EP2968470B1 (es)
JP (4) JP6698015B2 (es)
KR (1) KR20160029731A (es)
CN (1) CN105473154A (es)
AU (1) AU2014248768A1 (es)
BR (1) BR112015022181A8 (es)
CA (1) CA2904978A1 (es)
DK (1) DK2968470T3 (es)
ES (1) ES2853935T3 (es)
HK (1) HK1222331A1 (es)
MX (1) MX2015011846A (es)
PL (1) PL2968470T3 (es)
WO (1) WO2014164981A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11084860B2 (en) * 2013-03-12 2021-08-10 The General Hospital Corporation Modified Mullerian inhibiting substance (MIS) proteins and uses thereof for the treatment of diseases
AU2014321760A1 (en) 2013-09-20 2016-05-05 Massachusetts Eye And Ear Infirmary Uses of modified mullerian inhibiting substance (MIS) proteins for the treatment of neurodegenerative diseases
EP4008339A1 (en) * 2013-12-11 2022-06-08 The General Hospital Corporation Use of mullerian inhibiting substance (mis) proteins for contraception
MA41629A (fr) * 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
WO2018112168A1 (en) * 2016-12-14 2018-06-21 The General Hospital Corporation Mullerian inhibiting substance (mis) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation
CN107523586B (zh) * 2017-10-20 2020-03-17 广州万孚生物技术股份有限公司 免疫质粒及用于检测抗穆勒氏管激素的单抗、杂交瘤细胞及其制备方法和应用
WO2020044298A1 (en) * 2018-08-30 2020-03-05 Preglem Sa A novel use of the anti-müllerian hormone
AU2020282359A1 (en) 2019-05-31 2022-01-06 Laura DETTI Anti-Mullerian hormone receptor binding peptides
KR20220157360A (ko) * 2019-11-13 2022-11-29 셀매틱스 인크. 난소 노화의 치료를 위해 난포형성을 조절하는 조성물 및 방법
CN112251444B (zh) * 2020-10-21 2023-05-16 恺佧生物科技(上海)有限公司 一种改造的amh基因序列及利用其制备amh的方法
RU2770003C1 (ru) * 2021-04-05 2022-04-14 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Моноклональное антитело к С-концевому фрагменту антимюллерова гормона
CN115554403B (zh) * 2022-08-16 2024-03-08 山东大学 类固醇激素dhea作为受体adgrg2激动剂配体的应用
CN120591344A (zh) * 2025-06-13 2025-09-05 广州景旸生物科技有限公司 Col3a1蛋白的制备方法及其应用

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US224A (en) 1837-06-03 Improvement in cotton-presses
US4447A (en) 1846-04-04 Car- wheel
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308483D0 (en) 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
ATE78515T1 (de) 1984-10-05 1992-08-15 Genentech Inc Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung.
US4963495A (en) 1984-10-05 1990-10-16 Genentech, Inc. Secretion of heterologous proteins
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
US5359033A (en) 1985-10-30 1994-10-25 Biogen, Inc. Cleaved dimers of mullerian inhibiting substance-like polypeptides
US5427780A (en) 1985-10-30 1995-06-27 Biogen, Inc. Composition comprising Mullerian inhibiting substance-like polypeptides
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5010055A (en) 1986-06-24 1991-04-23 The General Hospital Corporation Use of EGF to reverse the contraceptive activity of MIS
US4753794A (en) 1986-06-24 1988-06-28 The General Hospital Corporation Use of mullerian inhibiting substance as a contraceptive agent
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
GB8723662D0 (en) 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
US5061641A (en) 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
US5057301A (en) 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
WO1989010971A1 (en) 1988-05-09 1989-11-16 The United States Of America, As Represented By Th Vector for secretion of proteins directly into periplasm or culture medium
US5759802A (en) 1988-10-26 1998-06-02 Tonen Corporation Production of human serum alubumin A
JPH02117384A (ja) * 1988-10-26 1990-05-01 Tonen Corp 酵母宿主によるヒト血清アルブミンａの製造
US5661126A (en) 1989-01-19 1997-08-26 The General Hospital Corporation Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5641671A (en) 1990-07-06 1997-06-24 Unilever Patent Holdings B.V. Production of active Pseudomonas glumae lipase in homologous or heterologous hosts
WO1992013951A1 (en) 1991-02-04 1992-08-20 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of human serum albumin in methylotrophic yeast cells
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
WO1994005311A1 (en) 1992-08-27 1994-03-17 Deakin Research Limited Retro-, inverso-, and retro-inverso synthetic peptide analogues
WO1994012649A2 (en) 1992-12-03 1994-06-09 Genzyme Corporation Gene therapy for cystic fibrosis
DE69431750T2 (de) 1993-04-22 2003-04-03 Skyepharma Inc., San Diego Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
BR9408072A (pt) 1993-11-16 1997-08-12 Depotech Corp Vesículas com liberação controlada de ativos
US5665557A (en) 1994-11-14 1997-09-09 Systemix, Inc. Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
US6495357B1 (en) 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
CA2234931C (en) 1995-10-16 2010-01-19 Dana-Farber Cancer Institute Novel expression vectors and methods of use
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP0971747B1 (en) 1996-10-28 2005-12-28 Amersham Health AS Contrast agents
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
US6361989B1 (en) 1997-10-13 2002-03-26 Novozymes A/S α-amylase and α-amylase variants
US6156552A (en) 1998-02-18 2000-12-05 Novo Nordisk A/S Lipase variants
US6428978B1 (en) * 1998-05-08 2002-08-06 Cohesion Technologies, Inc. Methods for the production of gelatin and full-length triple helical collagen in recombinant cells
US6323007B1 (en) 1998-09-18 2001-11-27 Novozymes A/S 2,6-β-D-fructan hydrolase enzyme and processes for using the enzyme
DK1323820T3 (da) 1998-10-28 2009-03-16 Genentech Inc Fremgangsmåde til faciliteret isolering af heterologe proteiner fra bakterieceller
JP4732591B2 (ja) 1999-03-29 2011-07-27 ノボザイムス アクティーゼルスカブ 分枝酵素活性を有するポリペプチド及びそれをコードする核酸
EP1074265A1 (en) 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
US6558939B1 (en) 1999-08-31 2003-05-06 Novozymes, A/S Proteases and variants thereof
US6673352B1 (en) 1999-09-14 2004-01-06 The General Hospital Corporation Use of Mullerian inhibiting substance for treating excess androgen states
CA2384991A1 (en) * 1999-09-14 2001-03-22 The General Hospital Corporation Use of mullerian inhibiting substance for treating excess androgen states
DE19944870A1 (de) 1999-09-18 2001-03-29 Aventis Pharma Gmbh Signalsequenzen zur Herstellung von Leu-Hirudin über Sekretion durch E. coli in das Kulturmedium
US6617143B1 (en) 1999-10-20 2003-09-09 Novozymes A/S Polypeptides having glucanotransferase activity and nucleic acids encoding same
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US6509181B1 (en) 2000-04-14 2003-01-21 Novozymes, A/S Polypeptides having haloperoxide activity
DE10108212A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
ES2350090T3 (es) 2001-08-20 2011-01-18 University Of Medicine And Dentistry Of New Jersey Niveles de sustancia inhibidora mulleriana y respuesta ovárica.
ES2425738T3 (es) * 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
AU2004276522B2 (en) 2003-09-26 2010-12-02 Merck Serono Sa Leader sequences for use in production of proteins
EP1858546A4 (en) 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp MODIFIED TRANSFERRINFUSION PROTEINS
CA2516364A1 (en) 2005-03-24 2006-09-24 University Of Otago Method of modulation
WO2007047504A2 (en) 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
EP1940450A4 (en) 2005-10-26 2010-12-29 Otago Innovation Ltd MODULATION METHOD
AU2008210538B2 (en) 2007-01-31 2013-06-06 Pelican Technology Holdings, Inc. Bacterial leader sequences for increased expression
WO2008116161A2 (en) * 2007-03-22 2008-09-25 The General Hospital Corporation Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states
EP2764874A1 (en) * 2007-07-17 2014-08-13 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic stem cells and uses thereof
EP2195028A2 (en) 2007-09-18 2010-06-16 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
US20120225824A1 (en) 2008-08-05 2012-09-06 The Trustees Of Columbia University In The City Of New York Mullerian inhibiting substance (mis) analogues
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
FR2993926A1 (fr) 2012-07-24 2014-01-31 Vianney Rabhi Turbomoteur basse-pression a combustion interne et/ou externe
US11084860B2 (en) 2013-03-12 2021-08-10 The General Hospital Corporation Modified Mullerian inhibiting substance (MIS) proteins and uses thereof for the treatment of diseases
AU2014321760A1 (en) 2013-09-20 2016-05-05 Massachusetts Eye And Ear Infirmary Uses of modified mullerian inhibiting substance (MIS) proteins for the treatment of neurodegenerative diseases
EP4008339A1 (en) 2013-12-11 2022-06-08 The General Hospital Corporation Use of mullerian inhibiting substance (mis) proteins for contraception
KR20230173105A (ko) 2021-03-22 2023-12-26 더 제너럴 하스피탈 코포레이션 사춘기 이전의 비인간 동물 및 인간에서 사춘기를 예방 또는 지연시키기 위한 조성물 및 방법

Also Published As

Publication number Publication date
US12497437B2 (en) 2025-12-16
DK2968470T3 (da) 2021-02-01
BR112015022181A8 (pt) 2018-01-23
PL2968470T3 (pl) 2021-05-31
US11084860B2 (en) 2021-08-10
EP2968470A4 (en) 2016-10-12
CA2904978A1 (en) 2014-10-09
JP2020074789A (ja) 2020-05-21
ES2853935T3 (es) 2021-09-20
JP7597511B2 (ja) 2024-12-10
AU2014248768A1 (en) 2015-09-24
JP6698015B2 (ja) 2020-05-27
EP2968470A1 (en) 2016-01-20
JP2024178382A (ja) 2024-12-24
US20160039898A1 (en) 2016-02-11
BR112015022181A2 (pt) 2017-11-21
JP2016518325A (ja) 2016-06-23
JP2022180637A (ja) 2022-12-06
WO2014164981A1 (en) 2014-10-09
KR20160029731A (ko) 2016-03-15
US20220041677A1 (en) 2022-02-10
CN105473154A (zh) 2016-04-06
HK1222331A1 (zh) 2017-06-30
EP2968470B1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
MX2015011846A (es) Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades.
NI201700032A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del higado graso no alcohólico
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
CO2018005361A2 (es) Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración
MX2016010854A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
CL2017000201A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112015019064A2 (pt) métodos de tratamento de melanoma
PE20250392A1 (es) Anticuerpos a la alfa-sinucleina y usos de los mismos
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
EA201591925A1 (ru) Терапевтические композиции и их применение
MX386896B (es) Composiciones y el uso de las mismas para incrementar la inmunidad terapéutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
CO2019014671A2 (es) Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso
AR095555A1 (es) Uso terapéutico de los anticuerpos dirigidos al factor de crecimiento de hepatocitos (hgf)
BR112017013300A2 (pt) alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
BR112015021265A2 (pt) métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний